Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma

被引:57
作者
Douglas-Jones, AG [1 ]
Collett, N [1 ]
Morgan, JM [1 ]
Jasani, B [1 ]
机构
[1] Univ Wales Coll Med, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales
关键词
breast carcinoma; oestrogen receptor; core biopsy;
D O I
10.1136/jcp.54.12.951
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims-The use of the H score (involving the assessment of intensity and distribution of positivity) on sections stained for the oestrogen receptor (ER) by immunocytochemistry (ICC) allows different samples to be compared and detailed correlations to be made between hormone receptor expression and morphology. This study assessed the reliability of core biopsy in predicting ER expression in the same tumour excised later at treatment. The distribution of ER within excised tumours was investigated. Methods-The distribution of ER positivity was investigated in 51 diagnostic core biopsies and across the diameter of 51 subsequently excised tumours in a field by field (magnification, x40; field diameter, 0.4 mm) assessment using the semiquantitive H scoring system. Results-The ER H score in diagnostic core biopsy was significantly higher (p = 0.05, paired rank test; overall mean, 130; n = 51) than the mean in the corresponding excised tumour (mean, 110; n = 51). There was a significant downward trend in ER positivity from the periphery of tumours towards the centre (p = 0.001). The reduction of ER positivity was 6 H score units (2%)/mm. If core biopsies were orientated with the tumour edge at one end no change in ER positivity with field number along the length of the core could be demonstrated. Conclusions-ER estimation in core biopsies correlated well with expression in tumours but ER expression was higher in the core biopsies than in the excised tumours. ER expression was higher at the periphery of tumours than at the centre. The higher ER expression in cores may reflect the higher chance of sampling the peripheral part of a tumour using a needle core.
引用
收藏
页码:951 / 955
页数:5
相关论文
共 21 条
  • [1] Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients
    Barnes, DM
    Harris, WH
    Smith, P
    Millis, RR
    Rubens, RD
    [J]. BRITISH JOURNAL OF CANCER, 1996, 74 (09) : 1445 - 1451
  • [2] ESTROGEN-RECEPTOR ENZYME-IMMUNOASSAY IN FINE-NEEDLE ASPIRATES FROM HUMAN-BREAST CANCER
    BORG, A
    FERNO, M
    IDVALL, I
    [J]. ACTA ONCOLOGICA, 1989, 28 (02) : 187 - 191
  • [3] Changing to core biopsy in an NHS breast screening unit
    Britton, PD
    Flower, CDR
    Freeman, AH
    Sinnatamby, R
    Warren, R
    Goddard, MJ
    Wight, DGD
    Bobrow, L
    [J]. CLINICAL RADIOLOGY, 1997, 52 (10) : 764 - 767
  • [4] Clarke M, 1998, LANCET, V351, P1451
  • [5] RECEPTOR HETEROGENEITY OF HUMAN-BREAST CANCER AS MEASURED BY MULTIPLE INTRATUMORAL ASSAYS OF ESTROGEN AND PROGESTERONE-RECEPTOR
    DAVIS, BW
    ZAVA, DT
    LOCHER, GW
    GOLDHIRSCH, A
    HARTMANN, WH
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (03): : 375 - 382
  • [6] REPRODUCIBILITY OF MEASUREMENTS OF ESTROGEN-RECEPTOR CONCENTRATION IN BREAST-CANCER
    HAWKINS, RA
    HILL, A
    FREEDMAN, B
    GORE, SM
    ROBERTS, MM
    FORREST, APM
    [J]. BRITISH JOURNAL OF CANCER, 1977, 36 (03) : 355 - 361
  • [7] IMPRINT CYTOLOGY IN IMMUNOCYTOCHEMICAL ANALYSIS OF ESTROGEN AND PROGESTERONE RECEPTORS OF BREAST-CARCINOMA
    HELIN, HJ
    ISOLA, JJ
    HELIN, MJ
    HELLE, MJ
    KROHN, KJE
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1989, 42 (10) : 1043 - 1045
  • [8] Leung SW, 1999, AM J CLIN PATHOL, V112, P50
  • [9] Cytological evaluation of biological prognostic markers from primary breast carcinomas
    Makris, A
    Allred, DC
    Powles, TJ
    Dowsett, M
    Fernando, IN
    Trott, PA
    Ashley, SE
    Ormerod, MG
    Titley, JC
    Osborne, CK
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1997, 44 (01) : 65 - 74
  • [10] MARRAZZO A, 1995, ANTICANCER RES, V15, P521